Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Salvatore Cottone

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Expert Opinion on Pharmacotherapy|August 23, 2017
Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinionEmanuele D'Amico, Tjalf Ziemssen, Salvatore Cottone
Clinicoeconomics and Outcomes Research : CEOR|April 16, 2025
Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in ItalyLuca Prosperini, Lorenzo Pradelli, Laura Santoni, et al.
Neurodegenerative Disease Management|September 7, 2022
Off-Adherence Keeping (OAK) observational study: intentional off-adherence immunomodulatory multiple sclerosis treatmentMarco Peresson, Salvatore Cottone, Vincenzo Brescia Morra, et al.
Journal of Clinical Medicine|June 2, 2021
Post-Acute COVID-19 Neurological Syndrome: A New Medical ChallengeDomenico Nuzzo, Sonya Vasto, Luca Scalisi, et al.
Life (Basel, Switzerland)|July 2, 2021
Comparison of the Intestinal Microbiome of Italian Patients with Multiple Sclerosis and Their Household RelativesPaola Galluzzo, Fanny Claire Capri, Luca Vecchioni, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Does glatiramer acetate provoke hepatitis in multiple sclerosis?Emanuele Sinagra, Dario Raimondo, Salvatore Cottone, et al.
Frontiers in Psychology|September 12, 2022
A nurse-led, telephone-based patient support program for improving adherence in patients with relapsing-remitting multiple sclerosis using interferon beta-1a: Lessons from a consumer-based survey on adveva<sup>®</sup> PSPSerena Barello, Damiano Paolicelli, Roberto Bergamaschi, et al.
Plos One|October 19, 2013
Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS studyFrancesco Patti, Vincenzo Brescia Morra, Maria Pia Amato, et al.
Journal of Visualized Surgery|October 29, 2017
Uniportal bilateral video-assisted sequential thoracoscopic extended thymectomyFrancesco Paolo Caronia, Ettore Arrigo, Sebastiano Trovato, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 29, 2011
Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II)Francesco Patti, Maria Pia Amato, Maria Trojano, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Expert Opinion on Pharmacotherapy|August 23, 2017
Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinionEmanuele D'Amico, Tjalf Ziemssen, Salvatore Cottone
Clinicoeconomics and Outcomes Research : CEOR|April 16, 2025
Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in ItalyLuca Prosperini, Lorenzo Pradelli, Laura Santoni, et al.
Neurodegenerative Disease Management|September 7, 2022
Off-Adherence Keeping (OAK) observational study: intentional off-adherence immunomodulatory multiple sclerosis treatmentMarco Peresson, Salvatore Cottone, Vincenzo Brescia Morra, et al.
Journal of Clinical Medicine|June 2, 2021
Post-Acute COVID-19 Neurological Syndrome: A New Medical ChallengeDomenico Nuzzo, Sonya Vasto, Luca Scalisi, et al.
Life (Basel, Switzerland)|July 2, 2021
Comparison of the Intestinal Microbiome of Italian Patients with Multiple Sclerosis and Their Household RelativesPaola Galluzzo, Fanny Claire Capri, Luca Vecchioni, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Does glatiramer acetate provoke hepatitis in multiple sclerosis?Emanuele Sinagra, Dario Raimondo, Salvatore Cottone, et al.
Frontiers in Psychology|September 12, 2022
A nurse-led, telephone-based patient support program for improving adherence in patients with relapsing-remitting multiple sclerosis using interferon beta-1a: Lessons from a consumer-based survey on adveva<sup>®</sup> PSPSerena Barello, Damiano Paolicelli, Roberto Bergamaschi, et al.
Plos One|October 19, 2013
Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS studyFrancesco Patti, Vincenzo Brescia Morra, Maria Pia Amato, et al.
Journal of Visualized Surgery|October 29, 2017
Uniportal bilateral video-assisted sequential thoracoscopic extended thymectomyFrancesco Paolo Caronia, Ettore Arrigo, Sebastiano Trovato, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 29, 2011
Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II)Francesco Patti, Maria Pia Amato, Maria Trojano, et al.
Pageof 3